en · de · es · fr · pt
epitalon-notes.peptides9002.com › News › Research Claims And Evidence Status — 2026 Update

Research Claims And Evidence Status — 2026 Update

By Editorial Desk · published 2025-12-03 · last reviewed 2026-01-13 · News

This is a working overview of pineal peptides, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-01-13. Anything still debated is marked as such rather than presented as settled.

Research Claims and Evidence Status

The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.

Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.

No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.

Epitalon Background and Nomenclature

Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.

The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.

Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.

Epitalon at a glance

PropertyValueNotes
Regulatory statusNot an approved drugMarketed in most countries as a research chemical
Main literature languageRussian and EnglishEarly reports concentrated in Russian journals
Typical stated purity≥95% by HPLCSupplier declaration, seldom independently verified
Principal studied endpointTelomerase activity in vitroMeasured in cultured human cells
Reported administration routesSubcutaneous, intranasalDescribed in exploratory use reports

Storage, Assay, and Regulatory Framework

Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.

Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.

Related pages on this site

Epitalon Background and Discovery

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.

Reference notes

According to IBGE (Brazilian Institute of Geography and Statistics) urban areas already concentrate 84.35% of the population, while the Southeast region remains the most populated one, with over 80 million inhabitants. The largest urban agglomerations in Brazil are São Paulo, Rio de Janeiro, and Belo Horizonte—all in the Southeastern Region—with 21.1, 12.3, and 5.1 million inhabitants respectively. The majority of state capitals are the largest cities in their states, except for Vitória, the capital of Espírito Santo, and Florianópolis, the capital of Santa Catarina.

== Further reading == John Ayto, "A Century of New Words", Series: Oxford Paperback Reference (2007) ISBN 0-19-921369-0 John Ayto, "Twentieth Century Words", Oxford University Press (1999) ISBN 0-19-860230-8

== Dietary recommendations == The National Academy of Medicine updated the Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for riboflavin in 1998. The EARs for riboflavin for women and men aged 14 and over are 0.9 mg/day and 1.1 mg/day, respectively; the RDAs are 1.1 and 1.3 mg/day, respectively. RDAs are higher than EARs to provide adequate intake levels for individuals with higher than average requirements. The RDA during pregnancy is 1.4 mg/day and the RDA for lactating females is 1.6 mg/day. For infants up to the age of 12 months, the Adequate Intake (AI) is 0.3–0.4 mg/day and for children aged 1–13 years the RDA increases with age from 0.5 to 0.9 mg/day. As for safety, the IOM sets tolerable upper intake levels (ULs) for vitamins and minerals when evidence is sufficient. In the case of riboflavin there is no UL, as there is no human data for adverse effects from high doses. Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes (DRIs). The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in United States. For women and men aged 15 and older the PRI is set at 1.6 mg/day. The PRI during pregnancy is 1.9 mg/day and the PRI for lactating females is 2.0 mg/day. For children aged 1–14 years the PRIs increase with age from 0.6 to 1.4 mg/day. These PRIs are higher than the US RDAs.

Sources: en.wikipedia.org

Notes from published material

For example, for the protein alkaline phosphatase, the staining solution is a mixture of 4-chloro-2-2 methylbenzenediazonium salt with 3-phospho-2-naphthoic acid-2'-4'-dimethyl aniline in Tris buffer. This stain is commercially sold as a kit for staining gels. If the protein is present, the mechanism of the reaction takes place in the following order: it starts with the de-phosphorylation of 3-phospho-2-naphthoic acid-2'-4'-dimethyl aniline by alkaline phosphatase (water is needed for the reaction). The phosphate group is released and replaced by an alcohol group from water. The electrophile 4- chloro-2-2 methylbenzenediazonium (Fast Red TR Diazonium salt) displaces the alcohol group forming the final product Red Azo dye. As its name implies, this is the final visible-red product of the reaction. In undergraduate academic experimentation of protein purification, the gel is usually run next to commercial purified samples to visualize the results and conclude whether or not purification was successful. Native gel electrophoresis is typically used in proteomics and metallomics. However, native PAGE is also used to scan genes (DNA) for unknown mutations as in single-strand conformation polymorphism.

==== Covalently linked gels ==== Three-dimensional covalently linked polymer networks are insoluble in all solvents, they merely swell in good solvents. Thermoresponsive polymer gels show a discontinuous change of the degree of swelling with temperature. At the volume phase transition temperature (VPTT) the degree of swelling changes drastically. Researchers try to exploit this behavior for temperature-induced drug delivery. In the swollen state, previously incorporated drugs are released easily by diffusion. More sophisticated "catch and release" techniques have been elaborated in combination with lithography and molecular imprinting.

is constant, it may be ignored and the general expression in theory, above, is obtained. All published stability constant values refer to the specific ionic medium used in their determination, and different values are obtained with different conditions, as illustrated for the complex CuL (L = glycinate). Furthermore, stability constant values depend on the specific electrolyte used, as the value of

=== XPS and EDS === X-ray photoelectron spectroscopy (XPS) and Energy-dispersive X-ray spectroscopy (EDS/EDX) are composition characterization techniques that use x-ray excitation of electrons to discrete energy levels to quantify chemical composition. These techniques provide characterization at surface depths of 1–10 nanometers, approximately the range of oxidation in plasma and corona treatments. In addition, these processes offer the benefit of characterizing microscopic variations in surface composition. In the context of plasma processed polymer surfaces, oxidized surfaces will obviously show a greater oxygen content. Elemental analysis allows for quantitative data to be obtained and used in the analysis of process efficiency.

Sources: en.wikipedia.org

Frequently asked questions

Has epitalon been studied in people?

Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.

What is the strongest evidence for its activity?

The most reproducible biochemical observation comes from cultured cells, where the peptide was reported to raise telomerase activity. Whether this translates into measurable health effects in animals or humans is not established.

Why is epitalon sold online?

It is offered as a research chemical for laboratory use, which places it outside the approval pathways applied to medicines. Buyers should expect documentation to differ between suppliers.

What is epitalon made of?

It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.

Network